Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Automated Oxygen Titration With the EMILY.AI Device During the Six-Minute Walk Test

16. november 2026 opdateret af: Aether Tech S.L.

Functional, Clinical, and Predictive Validation Study of the EMILY AI Device in Patients With Acute and Chronic Respiratory Failure: Exercise Substudy (Six-Minute Walk Test) in Ambulatory Patients

This study evaluates EMILY.AI, an investigational (non-CE-marked) smart oxygen valve that automatically adjusts the oxygen flow delivered to a patient.

Adults with chronic respiratory disease who need oxygen during exertion perform two six-minute walk tests on the same day, 30 minutes apart: one with oxygen adjusted automatically by EMILY.AI and one with a fixed oxygen flow delivered through the same device. The order is randomized and participants do not know which test uses automatic titration.

The study compares the time spent within the target saturation range, desaturation, oxygen use, walking distance, breathlessness and participant preference between the two tests. This substudy is part of clinical investigation FJD-EMILY-23-02, whose other substudies are registered in separate records.

Studieoversigt

Status

Rekruttering

Betingelser

Intervention / Behandling

Detaljeret beskrivelse

Background Patients with chronic respiratory disease often desaturate during exertion, and fixed-flow oxygen cannot follow the rapid changes in oxygen demand during walking and recovery. EMILY.AI combines a medical-grade oxygen valve with a rule-based algorithm that sets the oxygen flow.

Design Pilot, pragmatic, single-blind, randomized crossover study at Hospital Universitario Fundación Jiménez Díaz (Madrid, Spain). Each participant performs two supervised six-minute walk tests (6MWT) according to the American Thoracic Society guideline, separated by 30 minutes of rest: one with automatic titration by EMILY.AI and one with a fixed flow set by the physician, delivered through the same device so that the participant cannot tell them apart. The order of the two tests is randomized. Each test includes 6 minutes of walking and 2 minutes of standardized recovery.

Safety The medical team knows the device configuration and supervises the valve throughout each test.

Measurements SpO2, heart rate and respiratory rate are recorded with medical-grade pulse oximeters (Nonin, Masimo or Nihon Kohden models), together with distance walked, Borg dyspnoea score, oxygen delivered and participant-reported comfort, breathlessness and preference.

The protocol FJD-EMILY-23-02 also includes a substudy in the Respiratory Intermediate Care Unit and a substudy in a conventional hospital ward, registered separately.

Undersøgelsestype

Interventionel

Tilmelding (Anslået)

24

Fase

  • Ikke anvendelig

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiekontakt

  • Navn: Alba Naya Prieto, MD
  • Telefonnummer: +34 915 50 48 00
  • E-mail: alba.naya@fjd.es

Undersøgelse Kontakt Backup

  • Navn: Sarah Beatrice Heili Frades, MD, PhD
  • Telefonnummer: +34 915 50 48 00
  • E-mail: SHeili@fjd.es

Studiesteder

      • Madrid, Spanien, 28040
        • Rekruttering
        • Hospital Universitario Fundación Jiménez Díaz
        • Kontakt:
          • Sarah Beatrice Heili Frades Zimmermann MD, PhD
          • Telefonnummer: +34 915 50 48 00
          • E-mail: SHeili@fjd.es
        • Kontakt:
        • Ledende efterforsker:
          • Sarah Beatrice Heili Frades Zimmermann, MD, PhD

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

40 år til 90 år (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Beskrivelse

Inclusion Criteria:

  • Aged 40 to 90 years with a chronic respiratory disease.
  • Indication for exertional oxygen therapy, defined as SpO2 below 88% during a six-minute walk test and/or resting respiratory failure (PaO2 below 60 mmHg).
  • Able to understand the study and sign informed consent.

Exclusion Criteria:

  • Decompensated acute or chronic disease with severe organ involvement, such as cardiovascular disease.
  • Musculoskeletal or neurological disease preventing stable and safe walking.
  • Comorbidities or treatments that, by intensity or dose, limit performance of the tests or interpretation of the results (such as alcohol use, beta-blockers, or other neurological or psychiatric drugs).
  • Walking limitation preventing the six-minute walk test, or cardiovascular or connective tissue disease limiting accurate transcutaneous pulse oximetry.
  • Pregnancy or breastfeeding (women of childbearing potential require a negative pregnancy test at screening).

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: Randomiseret
  • Interventionel model: Crossover opgave
  • Maskning: Enkelt

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: EMILY.AI first, then fixed flow

First 6MWT with automatic titration by EMILY.AI; after 30 minutes of rest, second 6MWT with fixed-flow oxygen through the same device.

Standard care: constant oxygen flow set by the physician, delivered through the EMILY.AI device in fixed mode so that the participant cannot distinguish it from automatic titration.

Investigational smart oxygen valve with rule-based algorithm that adjusts oxygen flow every second from pulse-oximetry SpO2, heart rate and respiratory rate during walking and recovery.

Andre navne:
  • EMILY.AI Smart Valve
Eksperimentel: Fixed flow first, then EMILY.AI

First 6MWT with fixed-flow oxygen through the device; after 30 minutes of rest, second 6MWT with automatic titration by EMILY.AI.

Standard care: constant oxygen flow set by the physician, delivered through the EMILY.AI device in fixed mode so that the participant cannot distinguish it from automatic titration.

Investigational smart oxygen valve with rule-based algorithm that adjusts oxygen flow every second from pulse-oximetry SpO2, heart rate and respiratory rate during walking and recovery.

Andre navne:
  • EMILY.AI Smart Valve

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Percentage of time with SpO2 within the target range
Tidsramme: Day 1

Percentage of test time (6 minutes of walking plus 2 minutes of recovery) with SpO2, measured by pulse oximetry, within the predefined target range (88-92%), without delivering oxygen while SpO2 is above the range. Compared between the test with automatic titration by EMILY.AI and the test with fixed flow.

Day 1

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Percentage of test time with SpO2 below 88%
Tidsramme: Day 1

Percentage of test time (walking and recovery) with SpO2 below 88%, compared between conditions.

Day 1
Number of desaturation episodes with SpO2 below 88%
Tidsramme: Day 1

Number of episodes per test in which SpO2 falls below 88%, compared between conditions.

Day 1
Time to start of oxygen flow correction
Tidsramme: Day 1

Time in seconds from SpO2 leaving the target range (88-96%) to the start of an oxygen flow change, compared between conditions.

Day 1
Time to return of SpO2 to the target range
Tidsramme: Day 1

Time in seconds from SpO2 leaving the target range (88-96%) to its return to the range, compared between conditions.

Day 1
Percentage of test time with oxygen delivered while SpO2 is above 92%
Tidsramme: Day 1

Percentage of test time (walking and recovery) during which oxygen is delivered while SpO2 is above 92%, compared between conditions.

Day 1
Number of episodes with oxygen delivered while SpO2 is above 92%
Tidsramme: Day 1

Number of episodes per test in which oxygen is delivered while SpO2 is above 92%, compared between conditions.

Day 1
Total oxygen delivered
Tidsramme: Day 1

Total volume of oxygen delivered (litres) during each test including recovery, compared between conditions.

Day 1
Mean oxygen flow
Tidsramme: Day 1

Mean oxygen flow (litres per minute) delivered during each test including recovery, compared between conditions.

Day 1
Six-minute walk distance
Tidsramme: Day 1

Distance walked (metres), compared between conditions.

Day 1
Change in dyspnoea measured with the modified Borg Dyspnoea Scale
Tidsramme: Day 1: before and immediately after each six-minute walk test

Change from the start to the end of each test in dyspnoea measured with the modified Borg Dyspnoea Scale, which ranges from 0 (no breathlessness at all) to 10 (maximal breathlessness). Higher scores mean a worse outcome. Compared between conditions.

Day 1: before and immediately after each six-minute walk test
Maximum heart rate
Tidsramme: Day 1

Maximum heart rate (beats per minute) during each test, compared between conditions.

Day 1
Maximum respiratory rate
Tidsramme: Day 1

Maximum respiratory rate (breaths per minute) during each test, compared between conditions.

Day 1
Perceived difference in exercise capacity between the two tests
Tidsramme: Day 1: within 1 hour after the second six-minute walk test

Number of participants answering no, partially or yes to the question "Did you notice differences in your exercise capacity in either of the two tests?", and, if so, in which test. Categorical 3-option response, not a scored scale.

Day 1: within 1 hour after the second six-minute walk test
Perceived difference in breathlessness between the two tests
Tidsramme: Day 1: within 1 hour after the second six-minute walk test

Number of participants answering no, partially or yes to the question "Did you notice differences in shortness of breath in either of the two tests?", and, if so, in which test. Categorical 3-option response, not a scored scale.

Day 1: within 1 hour after the second six-minute walk test
Perceived difference in comfort of oxygen delivery between the two tests
Tidsramme: Day 1: within 1 hour after the second six-minute walk test

Number of participants answering no, partially or yes to the question "Did you notice differences in the comfort of oxygen delivery in either of the two tests?", and, if so, in which test. Categorical 3-option response, not a scored scale.

Day 1: within 1 hour after the second six-minute walk test
Preference between the two oxygen delivery systems
Tidsramme: Day 1: within 1 hour after the second six-minute walk test

Number of participants answering no, partially or yes to the question "Do you prefer either of the two oxygen systems used in the tests?", and, if so, which one. Categorical 3-option response, not a scored scale.

Day 1: within 1 hour after the second six-minute walk test
Preference for continuous automatic flow regulation at home
Tidsramme: Day 1: within 1 hour after the second six-minute walk test

Number of participants answering no, partially or yes to the question "Would you prefer your home oxygen system to regulate the oxygen flow continuously?". Categorical 3-option response, not a scored scale.

Day 1: within 1 hour after the second six-minute walk test
Preference for telemonitored home oxygen
Tidsramme: Day 1: within 1 hour after the second six-minute walk test

Number of participants answering no, partially or yes to the question "Would you prefer your home oxygen system to be telemonitored by the medical team?". Categorical 3-option response, not a scored scale.

Day 1: within 1 hour after the second six-minute walk test

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Sponsor

Samarbejdspartnere

Efterforskere

  • Ledende efterforsker: Sarah Beatrice Heili Frades, MD, PhD, MD, PhD, Hospital Universitario Fundación Jiménez Díaz

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

15. april 2026

Primær færdiggørelse (Anslået)

20. december 2026

Studieafslutning (Anslået)

20. december 2026

Datoer for studieregistrering

Først indsendt

28. oktober 2026

Først indsendt, der opfyldte QC-kriterier

11. november 2026

Først opslået (Faktiske)

16. november 2026

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

18. november 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

16. november 2026

Sidst verificeret

1. november 2026

Mere information

Begreber relateret til denne undersøgelse

Andre undersøgelses-id-numre

  • FJD-EMILY-23-02-TM6M
  • FJD-EMILY-23-02 (Anden identifikator: Aether Tech SL)

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

UBESLUTET

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ingen

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .